PRM37 Performance of NLP tool designed to identify and extract biologic drug infusion data from clinical notes  by Leng, J. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A187
software to identify potential infusion notes. We used the NLP software to extract 
drug and dosage information, and standardize results. Methods: Trained review-
ers compared the NLP extractions to source documents and judged whether the 
software correctly extracted and standardized data. The software contains a display 
window allowing reviewers to directly assess the NLP extraction. NLP was run on all 
notes, but note titles were selected for evaluation based on the likelihood of contain-
ing infusion data. Accuracy, described as the number of correct extractions divided 
by the number of reviewed notes, was used to evaluate NLP performance. NLP was 
considered acceptable when the lower bound of the 95% Confidence Interval (CI) 
reached 80% accurate. Results: The NLP was trained on 4,000 notes and the evalu-
ation phase reviewed 35,190 notes based on 255 note titles covering 93.1% of eligible 
notes. The overall accuracy rate was 94.0% [95%CI: 85.5-100%] 33,077 notes were 
correctly extracted, 1,950 failed to extract infusion data and 163 contained an incor-
rect extraction. The range of the lower bound of 95%CI for the 255 titles was 78.8-
100%; 247 (96.9%) titles had a lower bound > 80%. ConClusions: The NLP software 
demonstrated acceptable accuracy when extracting biologic DMARD infusion data 
for approximately 97% of note titles, suggesting that clinical notes are a reliable 
data source to identify biologic DMARD infusion data when coding is inconsistent.
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objeCtives: The mandated implementation of ICD-10-CM (International 
Classification of Diseases, Tenth Revision, Clinical Modification) codes in 2014 
challenges the health care community to accurately map ICD-9-CM (International 
Classification of Diseases, Ninth Revision, Clinical Modification) codes to these new 
codes, in order to preserve consistency and validity of medical conditions. The usage 
of current mapping systems, including the Centers for Medicare & Medicaid Services’ 
(CMS) General Equivalence Mappings (GEMs), is hindered by their limited definitions 
of medical conditions. Additional mappings for conditions could be complicated. 
Instead of a simple one-to-one code matching, a one-to-many or a many-to-one 
matching might be needed. A systematic approach is needed to overcome the limi-
tations and complexities. Methods: Nineteen Charlson Comorbidity Index (CCI) 
medical conditions plus 21 other conditions were chosen for mapping. CMS’ 2013 
GEMs were used whenever available. When no GEMs existed, other public and pro-
prietary mapping systems were utilized. When necessary, expertise in coding and 
clinical knowledge was leveraged to improve the mapping. Results: The 1646 unique 
ICD-9-CM codes required to fully define the 40 medical conditions, mapped to 3742 
unique ICD-10-CM codes. A total of 6355 code-to-code mappings were obtained: 1135 
(17.9%) had a one-to-one match, 3636 (57.2%) had a many-to-one match (ICD-10-CM 
less granular), 425 (6.7%) had a one-to-many match (ICD-10-CM more granular), and 
1159 (18.2%) had a more complicated, many-to-many match. No GEMs existed for 221 
code maps. ConClusions: GEMs provides a strict and limited mapping of many 
conditions necessitating additional work to fully define these conditions. When ICD-
10-CM codes are in effect, validation studies are needed to verify the accuracy of the 
proposed mappings, particularly for commonly used conditions such as CCI. The CCI’s 
reliability and specificity, particularly, must be maintained with the new ICD-10-CM 
codes in order to continue to be useful as an important research tool.
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objeCtives: Research using observational data is complex and costly due to mas-
sive size and disparate format. Consequently, scientists frequently use one data 
source when conducting a study, which can result in inaccurate reflection of the 
target population or insufficient sample sizes. Use of a Common Data Model (CDM) 
standardizes format across disparate observational databases, facilitating consist-
ent and efficient application of research methods. The objective of this study was 
to rapidly and efficiently estimate how well disparate sources reflect “known” 
population characteristics, utilizing standardized patient selection, analyses and 
visualization software on data that has been transformed into a CDM. Methods: 
Using CEWorks® software, AF patients treated with warfarin or NOA were selected 
from multiple Administrative Claims and EHR databases previously transformed 
into a CDM format. Rates of selected disease states were calculated using a CEWorks 
analysis module, and then compared to results published in a recent study. Results 
across disparate databases were imported into a visualization tool for further com-
parison among data sources. Results: Preliminary results indicate that rates of 
selected disease state across disparate databases are similar to those published 
in a previous study. Total number and percentage reported in the study for NOAC 
[10,789 - 35%] and warfarin [19,964 - 65%] patients matched comparably at 8,093 
[29%] NOAC patients and 20,133 [65%] warfarin patients in CDM version. Different 
data sources also show similar prevalence rates on selected disease state, although 
such similarities show some gaps introduced by region and other demographic vari-
ables. ConClusions: Use of a CDM enables rapid data analysis to be performed 
across multiple data sources, enabling meaningful comparisons across disparate 
data. Results are easily linked to data visualization tools for further analysis. This 
study has far reaching implications for data scientists using multiple, large data 
sources, and further study is in need to verify its practicality.
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the lowest proportion males (54%). Mean age was lowest in the hallucinogen (24 
years) and cannabis (26 years) cohorts; each consisted of 35% patients < 18. Over 
half the amphetamine cohort resided in the western and southwestern US. Major 
psychiatric comorbidity was present for 44% in the sedative cohort, compared to 
15% in the alcohol cohort. Median total post-index costs were lowest for the can-
nabis ($6,740) and alcohol ($6,830) cohorts, and highest for the sedative cohort 
($16,628). ConClusions: Patients with claims carrying diagnoses indicative of 
AUD/SUD are a highly heterogeneous group in terms of drug of abuse, demographic 
and clinical characteristics, and health care costs and utilization. Measures combin-
ing AUD and SUD patients may be more reflective of alcohol than other substances 
because AUD patients predominate.
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objeCtives: Researchers use the Healthcare Cost and Utilization Project (HCUP) 
Cost-to-Charge Ratio (CCR) File to translate total charges in the Nationwide Inpatient 
Sample (NIS) into accurate costs. We investigated the impact on cost estimates 
using four techniques for handling missing CCRs. Methods: This is a cross-sec-
tional study using nationally-representative hospitalization data in the US in 2011. 
We investigated four techniques including: 1) complete case analysis; 2a) using 
a reweighting technique recommended by HCUP; 2b) reweighting by adjustment 
cells; and 3) using hotdeck imputation by adjustment cells. We used five disease 
cohorts chosen to represent different sample sizes. We created a disease cohort 
data set with non-missing CCRs as a benchmark complete data set. We picked one 
state at a time and set their CCRs to missing to create a data set with missing CCR 
data. We compared the CCR-adjusted cost estimates (mean and total) from both 
data sets. To evaluate the quality of an estimator, we assessed bias, variance, and 
the mean squared error (MSE) of an estimator. Results: The range of missing rates 
was 1%-12%. The majority of states (> 84%) had missing CCR data in the range of 1% 
to 4%. In general, biases in magnitude and MSE of mean adjusted costs increased as 
missing rates increased. Complete case analysis, the reweighting technique recom-
mended by HCUP, and reweighting by adjustment cells performed similarly in mean 
cost estimation. Reweighting techniques performed better in total cost estimation. 
Complete case analysis underestimated total costs and became worse as missing 
rates increased. ConClusions: In NIS data, to handle missing CCRs, when miss-
ing data < 4%, researchers will obtain similar mean cost estimates using complete 
case analysis, the reweighting technique recommended by HCUP, or reweighting by 
adjustment cells. However, if total cost is the estimate of interest, researchers should 
adopt either reweighting techniques in order to avoid underestimation.
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objeCtives: While patients with end-stage renal disease (ESRD) represent only 1 
percent of Medicare beneficiaries, this population accounts for 8 percent of total 
Medicare spending. The disproportionate cost of treating ESRD has resulted in a high 
level of monitoring and policy focus. A number of public databases currently exist 
for study of the ESRD program in the US, but these databases are difficult to use and 
integrate for policy analysis of this program. Objective was to develop an integrated 
ESRD “data warehouse” with GIS capabilities from publicly-available dialysis patient 
and provider data and general population statistics, to enable a broadened scope of 
applications for policy analysis. Methods: ESRD-related datasets were collected 
from Medicare sources and integrated into a relational database management sys-
tem. Datasets included Renal and Hospital Cost Reports, Dialysis Facility Reports, 
the Dialysis Facility Compare database, and patient prevalence reports. Dialysis 
provider and patient addresses were geocoded and linked to spatial data files and 
general population data obtained from Census Bureau websites. Validation and 
outlier handling rules were created for most data and were applied either during 
the build/update process or at the point of analysis. Longitudinal datasets were 
created for trend analysis. Data are updated quarterly to keep the database cur-
rent. Results: The ESRD provider database contains over 6000 cost, utilization, 
quality, demographic and geographic variables, covering 100% of current Medicare 
ESRD providers (N= 6288 facilities). Approximately 9% are hospital-based units and 
91% are free-standing facilities. Depending on data source, the database covers 
between 6 and 14 calendar years (2001-14). Quality of the data varies, but for most 
applications, outlier and missing observations are less than 10%. ConClusions: 
Public datasets of ESRD-related information can be integrated with general popula-
tion data and a GIS to support high-quality and cost-effective economic and clinical 
policy studies that would not otherwise be feasible.
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objeCtives: Infusions of outpatient medications including biologic Disease 
Modifying Anti-Rheumatic Drugs (DMARDs) administered at Veterans Health 
Administration (VHA) facilities are well documented in the electronic medical 
record but data are not consistently entered into the pharmacy dispensing or nurse 
administration structured data sources. Although CPT codes can be used to identify 
many infusion events but inconsistent coding does not allow estimation of the 
administered dose. To address this, we developed Natural Language Processing (NLP) 
